文献速递儿科与产科急症心脑血管急症

理解阴性临床试验结果:劳拉西泮与地西泮治疗小儿癫痫持续状态的贝叶斯分析

Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus.
PubMed 文献 · Ann Emerg Med · 2017-01-01
一句话结论贝叶斯分析显示,劳拉西泮治疗小儿癫痫持续状态的疗效与安全性很可能非劣效且实际等效于地西泮,尽管原试验未证明优效性。

该研究是对小儿癫痫研究(一项比较劳拉西泮与地西泮治疗小儿癫痫持续状态的随机临床试验)疗效与安全性结果的二次分析,采用贝叶斯层次模型并纳入唯一一项已发表的前瞻性小儿癫痫研究结果,对合并程度进行敏感性分析,评估优效性、非劣效性(界值<-10%)和实际等效性(±10%内)三种汇总分析。结果与原试验经典分析一致,未证明劳拉西泮优于地西泮;劳拉西泮真实疗效有95%概率在66%至80%范围内;对于疗效和安全性结局,劳拉西泮非劣效于地西泮的概率大于95%,两药实际等效的概率大于90%。结论认为贝叶斯分析可提供阴性试验结果更有用的信息,在小儿癫痫持续状态中劳拉西泮很可能非劣效且实际等效于地西泮。

要点

  • 原随机试验未证明劳拉西泮优于地西泮,但贝叶斯分析显示劳拉西泮真实疗效有95%概率在66%至80%范围内。
  • 对于疗效和安全性结局,劳拉西泮非劣效于地西泮的概率大于95%,两药实际等效(±10%内)的概率大于90%。
  • 结果主要由当前研究(n=273)驱动,因样本量大于先前小儿研究(n=61)。
  • 贝叶斯分析通过估计假设概率,可为阴性试验结果提供更实用的解释,并纳入先前证据。

适用人群与场景

  • 小儿癫痫持续状态患者,来自小儿癫痫研究随机临床试验及唯一一项已发表的前瞻性小儿癫痫研究。

诊断标准与关键阈值

  • 非劣效性界值为<-10%;实际等效性定义为在±10%范围内。

研究设计与关键结果

  • 研究类型为随机临床试验的二次贝叶斯分析,纳入当前研究(n=273)和先前小儿研究(n=61)。
  • 未证明劳拉西泮优于地西泮;劳拉西泮真实疗效有95%概率在66%至80%范围内。
  • 疗效和安全性结局中,劳拉西泮非劣效于地西泮的概率大于95%,实际等效的概率大于90%。

证据类型、等级与局限

  • 证据类型为随机临床试验的二次贝叶斯分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为贝叶斯分析可提供阴性试验结果更实用的信息;在小儿癫痫持续状态中,劳拉西泮很可能非劣效且实际等效于地西泮。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: We demonstrate the application of a Bayesian approach to a recent negative clinical trial result. A Bayesian analysis of such a trial can provide a more useful interpretation of results and can incorporate previous evidence.

METHODS: This was a secondary analysis of the efficacy and safety results of the Pediatric Seizure Study, a randomized clinical trial of lorazepam versus diazepam for pediatric status epilepticus. We included the published results from the only prospective pediatric study of status in a Bayesian hierarchic model, and we performed sensitivity analyses on the amount of pooling between studies. We evaluated 3 summary analyses for the results: superiority, noninferiority (margin <-10%), and practical equivalence (within ±10%).

RESULTS: Consistent with the original study's classic analysis of study results, we did not demonstrate superiority of lorazepam over diazepam. There is a 95% probability that the true efficacy of lorazepam is in the range of 66% to 80%. For both the efficacy and safety outcomes, there was greater than 95% probability that lorazepam is noninferior to diazepam, and there was greater than 90% probability that the 2 medications are practically equivalent. The results were largely driven by the current study because of the sample sizes of our study (n=273) and the previous pediatric study (n=61).

CONCLUSION: Because Bayesian analysis estimates the probability of one or more hypotheses, such an approach can provide more useful information about the meaning of the results of a negative trial outcome. In the case of pediatric status epilepticus, it is highly likely that lorazepam is noninferior and practically equivalent to diazepam.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Chamberlain DB, Chamberlain JM. Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus. Ann Emerg Med. 2017. PMID: 27993298. doi:10.1016/j.annemergmed.2016.08.449

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。